Sareum Hldgs Plc Cash Flow Conversion Efficiency

Latest as of December 2025: -1.269x

Sareum Hldgs Plc cash flow conversion efficiency. Based on the latest financial reports, Sareum Hldgs Plc (SAR) has a cash flow conversion efficiency ratio of -1.269x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.51 Million ≈ $-184.33 USD) by net assets (GBX1.19 Million ≈ $145.28 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sareum Hldgs Plc (2004–2025)

Cash flow conversion efficiency of Sareum Hldgs Plc from 2004 to 2025. This chart illustrates how Sareum Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sareum Hldgs Plc (SAR) stock price for real-time trading data and today's change.

Sareum Hldgs Plc Cash Flow Conversion Ratio Explained

Sareum Hldgs Plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sareum Hldgs Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sareum Hldgs Plc ranked by their cash flow conversion efficiency. Also see SAR market cap for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
VEGANO FOODS INC.
F:P0D0
N/A
CANDELARIA MINING CORP
F:29LN
-0.045x
London Finance and Investment Group PLC
LSE:LFI
-0.040x
SMG EUROPEAN RECOV. EO 1
F:RCVR
N/A
Provexis plc
LSE:PXS
-0.307x
Robinson plc
LSE:RBN
0.185x
Highbank Resources Ltd.
V:HBK
0.002x
Portmeirion Group
LSE:PMGR
0.030x

Annual Cash Flow Conversion Efficiency for Sareum Hldgs Plc (2004–2025)

The table below shows the annual cash flow conversion efficiency of Sareum Hldgs Plc from 2004 to 2025. Review SAR free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 GBX2.28 Million
≈ $277.05
GBX-2.55 Million
≈ $-310.38
-1.120x +39.57%
2024-06-30 GBX2.11 Million
≈ $257.21
GBX-3.92 Million
≈ $-476.83
-1.854x +34.57%
2023-06-30 GBX1.15 Million
≈ $140.29
GBX-3.27 Million
≈ $-397.50
-2.833x -475.87%
2022-06-30 GBX4.33 Million
≈ $526.96
GBX-2.13 Million
≈ $-259.28
-0.492x +12.44%
2021-06-30 GBX2.80 Million
≈ $340.07
GBX-1.57 Million
≈ $-191.10
-0.562x -24.65%
2020-06-30 GBX1.80 Million
≈ $219.44
GBX-813.09K
≈ $-98.93
-0.451x +60.95%
2019-06-30 GBX1.09 Million
≈ $133.13
GBX-1.26 Million
≈ $-153.70
-1.154x -18.37%
2018-06-30 GBX1.63 Million
≈ $198.64
GBX-1.59 Million
≈ $-193.74
-0.975x -371.10%
2017-06-30 GBX2.35 Million
≈ $285.39
GBX843.87K
≈ $102.67
0.360x +198.88%
2016-06-30 GBX1.86 Million
≈ $226.74
GBX-678.00K
≈ $-82.49
-0.364x -5.22%
2015-06-30 GBX1.86 Million
≈ $226.69
GBX-644.24K
≈ $-78.39
-0.346x +24.16%
2014-06-30 GBX1.72 Million
≈ $209.58
GBX-785.34K
≈ $-95.55
-0.456x +65.64%
2013-06-30 GBX439.10K
≈ $53.43
GBX-582.74K
≈ $-70.90
-1.327x -5.88%
2012-06-30 GBX480.38K
≈ $58.45
GBX-602.14K
≈ $-73.26
-1.253x -100.37%
2011-06-30 GBX876.00K
≈ $106.58
GBX-548.00K
≈ $-66.68
-0.626x +37.68%
2010-06-30 GBX523.00K
≈ $63.63
GBX-525.00K
≈ $-63.88
-1.004x +54.03%
2009-06-30 GBX327.00K
≈ $39.79
GBX-714.00K
≈ $-86.87
-2.183x -81.42%
2008-06-30 GBX1.40 Million
≈ $170.34
GBX-1.69 Million
≈ $-205.02
-1.204x -579.37%
2007-06-30 GBX1.37 Million
≈ $166.20
GBX-242.00K
≈ $-29.44
-0.177x +13.59%
2006-06-30 GBX1.20 Million
≈ $145.40
GBX-245.00K
≈ $-29.81
-0.205x +82.42%
2005-06-30 GBX1.32 Million
≈ $160.48
GBX-1.54 Million
≈ $-187.13
-1.166x -2128.90%
2004-06-30 GBX-87.00K
≈ $-10.59
GBX-5.00K
≈ $-0.61
0.057x --

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$257.11K
GBX2.11 Billion GBX
Market Cap Rank
#31297 Global
#997 in UK
Share Price
GBX15.25
Change (1 day)
+0.00%
52-Week Range
GBX12.00 - GBX37.00
All Time High
GBX457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more